VANCOUVER, British Columbia, July 2, 2026
Cannabix Technologies Inc. announced the successful detection of methamphetamine and amphetamine compounds in human breath using its Cannabix Marijuana Breath Test (MBT) platform, marking a significant advancement in breath-based drug testing technology. Human breath samples were collected using the company’s Breath Collection Unit (BCU) and analyzed by Omega Laboratories Inc. using liquid chromatography-mass spectrometry (LC-MS). According to the company, the findings demonstrate that its proprietary breath collection system can capture and identify amphetamine-class stimulants that are typically present in exhaled breath at extremely low concentrations. The results expand the potential capabilities of the Cannabix MBT beyond THC detection, creating new opportunities for non-invasive drug screening in workplace safety, transportation, industrial operations, and law enforcement.
Detection Demonstrates High Sensitivity of Breath Testing Platform
The successful identification of methamphetamine and amphetamine validates the sensitivity of the Cannabix Marijuana Breath Test, which combines the Breath Collection Unit, disposable Breath Cartridges, and Omega Laboratories’ laboratory-developed LC-MS testing method. Unlike urine or blood testing, human breath contains only microscopic aerosol particles carrying trace amounts of non-volatile drug compounds, making accurate detection technically challenging. Cannabix reported that its technology successfully captured these compounds despite their extremely low concentrations, demonstrating the platform’s capability to support reliable laboratory analysis while maintaining a legally defensible chain of custody. The achievement represents an important technological milestone in the development of advanced breath-based diagnostic testing.
Technology Could Expand Workplace and Law Enforcement Applications
Cannabix believes the ability to detect amphetamine-class stimulants alongside cannabis could significantly broaden the commercial applications of its breath testing platform. Industries such as transportation, construction, manufacturing, mining, and resource extraction, where impairment can present serious safety risks, may benefit from rapid, non-invasive testing methods capable of detecting multiple drug classes. The company also sees opportunities within law enforcement by providing scientifically validated breath-based testing solutions that reduce the need for more invasive biological sample collection. Expanding the platform beyond THC could increase its value for organizations seeking comprehensive impairment management tools while supporting workplace safety and regulatory compliance.
Advertisement
Cannabix Advances Next-Generation Breath Diagnostics
Cannabix Technologies is focused on developing innovative breath testing technologies for detecting marijuana, alcohol, and other impairing substances through non-invasive sample collection. The latest findings suggest that the company’s proprietary platform may evolve into a broader multi-drug breath testing solution, capable of identifying substances beyond cannabis while leveraging advanced laboratory analysis. According to Chief Executive Officer Rav Mlait, detecting methamphetamine and amphetamine in human breath demonstrates the efficiency of the company’s sample collection technology and highlights its potential to deliver expanded diagnostic capabilities for safety-sensitive industries. As development continues, Cannabix aims to strengthen the scientific and commercial value of its breath testing platform by supporting reliable, laboratory-confirmed detection of multiple drugs through a single, non-invasive testing approach.
Source: Cannabix Technologies press release
